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The aging risk factor for Parkinson’s disease is described in terms of speciﬁc disease markers including
mitochondrial and gene dysfunctions relevant to energy metabolism. This review details evidence for the
ability of nutritional agents to manage these aging risk factors. The combination of alpha lipoic acid, acetyl-
L-carnitine, coenzyme Q10, and melatonin supports energy metabolism via carbohydrate and fatty acid
utilization, assists electron transport and adenosine triphosphate synthesis, counters oxidative and nitro-
sative stress, and raises defenses against protein misfolding, inﬂammatory stimuli, iron, and other endog-
enous or xenobiotic toxins. These effects are supported by gene expression via the antioxidant response
element (ARE; Keap/Nrf2 pathway), and by peroxisome proliferator-activated receptor gamma co-activator
1 alpha (PGC-1 alpha), a transcription coactivator, which regulates gene expression for energy metabolism
and mitochondrial biogenesis, and maintains the structural integrity of mitochondria. The effectiveness and
synergies of the combination against disease risks are discussed in relation to gene action, dopamine cell
loss, and the accumulation and spread of pathology via misfolded alpha-synuclein. In addition there are
potential synergies to support a neurorestorative role via glial derived neurotrophic factor expression.
 2014 The Author. Publ ishe d by Els evier Inc .   Open access under CC BY license.1. Introduction
Progress is needed to improve outcomes for patients with Par-
kinson’s disease (PD). Treatments aimed at correcting the charac-
teristic dopaminergic deﬁcits, although they are effective in
controling symptoms, fail to prevent progression of the underlying
disease. The aging process is the greatest risk factor for the devel-
opment and progression of the typical (sporadic) form of the dis-
ease (PD) (Collier et al., 2011; Hindle, 2010). It thus seems logical to
ask whether agents known to directly inﬂuence aspects of the aging
process, can play a role in the management of this risk for PD.
Many reviews have examined the role of mitochondrial
dysfunction, oxidative stress and energy production in aging, and
PD (e.g., Cassarino and Bennett, 1999; Hauser and Hastings, 2013;
Henchcliffe and Beal, 2008; Martin, 2010; Nicholls and Budd,
2000; Olanow, 1993; Shigenaga et al., 1994). Although not fully
understood, there is a reduction in the efﬁciency of theiences, University of Bristol,
9228; fax: þ44 117 9304263.
Inc.   Open access under CC BY license.mitochondrial electron transport chain (ETC) and adenosine
triphosphate (ATP) production with age, associated with leakage
of electrons and an excess production of superoxide anions,
leading potentially to the production of further reactive oxygen
radicals via Fenton chemistry, and to the formation of damaging
nitrogen species (Beckman, 1994; Halliwell, 1992; Harman, 1956).
Mitochondrial enzymes of the Krebs tricarboxylic acid (TCA) cycle,
the protein complexes of the ETC, the lipid cristae which embed
these complexes and mitochondrial DNA are thus all at a high risk
of damage in the course of aging. In aging and in PD, under-
expression of genes associated with energy metabolism, com-
pounds these adverse events in mitochondria. Moreover this
change of gene expression is a feature of the preclinical stage of PD
(Zheng et al., 2010). When endogenous defenses can no longer
resist these stresses, neuropathologic changes may accumulate,
notably in dopamine neurons, which are rendered especially
susceptible to the combined effects of energy deﬁcit and oxidative
stress by the catechol structure and metabolism of dopamine
(Cohen, 1994; Kristal et al., 2001; Lamensdorf et al., 2000;
Marchitti et al., 2007).
Abnormalities in PD also occur outside the central dopami-
nergic pathways, as there is evidence of widespread dysfunction
(shown by biochemical change, gene underexpression, pathology,
and functional deﬁcit) in other non-dopamine central neurons,
autonomic and sensory pathways, and peripheral structures
including nonneural tissue (Beach et al., 2010; Braak et al., 2003;
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et al., 1992; Hindle, 2010; Jain et al., 2011; Jellinger, 1999;
Mytilineou et al.,1994; Zheng et al., 2010), and many patients
later develop cortical pathology (Braak et al., 2003) and dementia
(Hindle, 2010).
Some of the changes in the central nervous system associated
with PD are also found, in less severe form, in normal aging tissue.
Thus, the reduction in dopamine, complex I, reduced glutathione,
alpha ketoglutarate dehydrogenase, and the increase in markers
for oxidative stress, alpha synuclein, amyloid, iron and mito-
chondrial DNA deletions, which are found in PD, also occur in the
course of normal aging (Bender et al., 2006; Braidy et al., 2011;
Carretero et al., 2009; Chu and Kordower, 2007; Collier et al.,
2011; Darbin, 2012; Hauser and Hastings, 2013; Hindle, 2010;
Long et al., 2009a), the latter including a reduction of the anti-
oxidant defense signal nuclear factor (erythroid-derived 2)-like2
(Nrf2) (Suh et al., 2004; Tufekci et al., 2011), and the transcription
regulator for energy metabolism, peroxisome proliferator-
activated receptor gamma co-activator 1 alpha (PGC-1alpha)
(Jiang et al., 2013), as well as ATP and nicotinamide adenine
dinucleoide (NADþ) (Braidy et al., 2011; Jiang et al., 2013).
This selective review discusses evidence for speciﬁc properties
of alpha lipoic acid, acetyl-L-carnitine, coenzyme Q10, and mela-
tonin, which can manage these age related risks relevant to PD.
In practice, case history evidence shows that, when used in com-
bination, they appear effective in restraining progression
(Phillipson, 2013). This result indicates that support of mito-
chondrial function and gene expression by these agents, may be
sufﬁcient to signiﬁcantly reduce the impact of some aging risk
factors for PD.
2. R-alpha-lipoic acid
2.1. Role in energy metabolism
The extraction of energy from carbohydrate sources proceeds
via metabolism to pyruvate, followed by transport across the
mitochondrial inner membrane to the matrix, and conversion to
acetyl coenzyme A (acetylCoA) by the giant multienzyme complex
pyruvate dehydrogenase (PDH). The reaction requires thiamine
pyrophosphate, lipoic acid, NADþ, and coenzyme A. In mamma-
lian species PDH may consist of more than 100 enzyme molecules,
comprising 20e30 pyruvate decarboxylase units, 60 lipoate
transacetylase and 20e30 lipoate dehydrogenase units (enzymes
E1, E2, and E3, respectively). As each E2 covalently binds 2 lipoate
molecules, the whole complex requires 120 molecules of lipoic
acid for optimal function. Overall the reaction yields carbon di-
oxide, nicotinamide adenine dinucleotide (NADH) and acetylCoA.
AcetylCoA provides a common end stage intermediate of meta-
bolism for both carbohydrates and beta oxidation of fatty
acids and enters the TCA cycle for further processing via citrate
and isocitrate to alpha-ketoglutarate. The conversion of alpha-
ketoglutarate to succinylCoA by alpha-ketoglutarate dehydroge-
nase (KGDH) is considered rate limiting for the whole cycle. KGDH
is a giant multienzyme complex with many similarities to PDH,
converting NADþ to NADH, yielding carbon dioxide, consuming
coenzyme A and requiring lipoic acid (Zubay, 1998).
2.2. Inﬂuence of aging and PD
Both PDH and KGDH are sensitive to inhibition by free radical
production arising from peroxidation of membrane lipids, which
is associated with the aging process in mitochondria (Long et al.,
2009b; reviewed in Packer and Cadenas, 2011). A major alde-
hyde product of lipid peroxidation is 4-hydroxy-2-nonenal (HNE).In vitro testing of puriﬁed PDH and KGDH shows that HNE inhibits
both enzymes by targeting covalently bound lipoate on E2
(Humphries and Szweda, 1998). Moreover, thiols, including lipoic
acid, provide protection against HNE-induced inactivation of
lipoyl-containing complexes in mitochondria (Korotchkina et al.,
2001). Glutathione, the major cellular thiol antioxidant, present
in millimolar concentrations, is also able to protect KGDH against
H2O2 and HNE toxicity by forming reversible disulphide adducts
with lipoic acid (Applegate et al., 2008). Oxidative stress and lipid
peroxidation thus pose a threat to energy production via the in-
hibition of PDH and KGDH.
Basal levels of HNE are reported as <1mM and subtoxic con-
centrations between 0.5 and 5.0 mM (Petersen and Doorn, 2004).
HNE is normally removed by glutathione conjugation and is the
major disposal route. Increased oxidation of reduced glutathione
in the early stages of PD (Sian et al., 1994), suggests that there is an
increased risk to key TCA cycle enzymes by HNE-induced inhibi-
tion. Since it requires 25e50 mM HNE to substantially inhibit pu-
riﬁed PDH and KGDH in vitro (Humphries and Szweda, 1998), it
seems that a more than 10-fold increase in HNE is needed to
inhibit NADH production by the cycle. A reported 10-fold increase
in “cholesterol-lipid hydroperoxides” in PD brain (Dexter et al.,
1994), suggests that this degree of oxidative stress may be sufﬁ-
cient to cause signiﬁcant PDH and KGDH inhibition in vivo. In
addition, a 6-fold increase in the presence of HNE-bound proteins
in the substantia nigra has been reported in patients who died
with PD (Yoritaka et al., 1996). Furthermore, an immunohisto-
chemical study of KGDH in PD found reduced staining in sub-
stantia nigra especially in the lateral one third, correlating roughly
with severity of degeneration (Mizuno et al., 1994). In brain areas
not affected by neurodegeneration, another study revealed that
KGDH activity in the cerebellum is reduced by 50% in PD. Because
the enzyme proteins appeared normal, it was suggested that
reactivation of the protein, presumably with cofactors, may be
useful (Gibson et al., 2003). These results suggest that there is a
widespread KGDH deﬁcit in PD which is not secondary to
degenerative change, but which may result in part from an in-
crease in oxidative stress associated with progression of disease.
More evidence of a widespread state of oxidative stress in PD is
noted in the following sections.
Procedures aimed at raising glutathione and lipoic acid levels
to relieve inhibition of PDH and KGDH may thus facilitate the
supply of NADH and succinate to feed the ETC, via complex I and II
respectively, thereby supporting mitochondrial respiration
(Humphries and Szweda, 1998).
2.3. Experimental studies
Lipoic acid is a direct and indirect antioxidant. In vitro it is able
to scavenge a variety of reactive oxygen species including super-
oxide, nitric oxide, peroxynitrite and the hydroxyl anion, and can
regenerate vitamins C and E (Packer, 1994). Furthermore, it is able
to chelate a variety of transitional metals including Fe3þ and
Cu2þ, which may play a role in the continuation of neuro-
degeneration by promoting oxidative stress (Suh et al., 2005;
Youdim and Lavie, 1994).
However, perhaps a key property of lipoate is the ability to act
as an indirect antioxidant via the antioxidant response element
(ARE). This involves induction of phase II antioxidants via the
Keap1/Nrf2/ARE pathway, which controls the expression of more
than 200 genes, including those required for reduced glutathione
(GSH) synthesis (Kwak et al., 2003; Shay et al., 2009; Suh et al.,
2004). The regulation of GSH involves glutamate cysteine ligase,
glutathione synthase, glutathione S-transferase, glutathione
peroxidase, and reductase, all of which respond to Nrf2 control of
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vide support to counter the GSH deﬁcit in PD and inhibition of
PDH and KGDH by the products of lipid peroxidation. Further-
more, the induction of aldehyde dehydrogenase (ALDH), which
also occurs on Nrf2 activation (Calkins et al., 2009), may promote
metabolism of HNE.
In vitro testing of a variety of cell lines including astroglia and
neuroblastoma, has conﬁrmed that lipoic acid can restore GSH in
GSH depleted cells, and also protect complex I inhibition induced by
GSH depletion (Bharat et al., 2002; Flier et al., 2002; Han et al.,
1997). This latter effect is signiﬁcant in view of the reduction in
the activity of complex I in PD (Schapira et al., 1990).
In vivo, lipoic acid decreases the level of lipid peroxidation,
increases GSH, and enhances the activities of several mitochon-
drial enzymes including KGDH, succinate dehydrogenase (com-
plex II), and NADH dehydrogenase (complex I) in aged animals
(Arivazhagan et al., 2001; Jiang et al., 2013). Reduction of the
intracellular concentration of GSH can also lead to persistent in-
hibition of complex I and inhibition of cellular respiration in the
presence of nitric oxide (NO). GSH protects the enzyme either by
preventing nitrosylation of critical thiols or by removing NO from
nitrosylated sites (Clementi et al., 1998; Moncada and Bolanos,
2006). Lipoic acid may thus not only improve the supply of sub-
strate to complex I via PDH and KGDH, but protect complex I in
cooperation with GSH.
Two other signiﬁcant responses to the induction of the Nrf2/ARE
pathway by lipoic acid are the increased expression of NAD(P)H,
quinone oxoreductase (NQO1), and ferritin. NQO1 will be discussed
in more detail later, together with coenzyme Q, with which it ap-
pears to cooperate to assist in electron transport and control
oxidative stress. Ferritin is an intracellular iron binding protein,
which sequesters free iron and can thus prevent Fenton chemistry
from exacerbating oxidative stress. Furthermore, Nrf2 dependent
induction of catalase, thioredoxin reductase, and superoxide dis-
mutase (Calkins et al., 2009) adds signiﬁcantly to neuroprotective
defenses.
Additional potentially beneﬁcial responses are induction of
several genes involved in the conversion of glucose to pyruvate, the
expression of isocitrate dehydrogenase and pyruvate dehydroge-
nase (facilitating energy production), induction of dopa decarbox-
ylase (facilitating dopamine synthesis), nitric oxide synthase
inhibitor proteins, chaperone and proteosome proteins (involved in
the recognition, repair, and removal of damaged proteins), and
reduction of inﬂammatory signals (Calkins et al., 2009; Kwak et al.,
2003; Suh et al., 2004). Energy metabolism may be further inﬂu-
enced by lipoic acid, via an increase in ATP synthesis (Zimmer et al.,
1991), and via an insulin-like effect, increasing glucose uptake in
neural tissue of aging rats (Jiang et al., 2013).
It seems that Nrf2-associated responses occur primarily in as-
trocytes, indicating that glial-neuronal cross talk is largely
responsible for these neuroprotective properties (Calkins et al.,
2009). However, neuronal cultures lacking astrocytes can also
display Nrf2 dependent protection against toxic stimuli (Tufekci
et al., 2011).
The evidence suggesting a possible neuroprotective role for Nrf2
signals, has been tested directly in various mouse models of
experimental parkinsonism in which Nrf2 deﬁcient mice show
reduced resistance to 6-hydroxydopamine, 1-methyl-4-phenyl-1, 2,
3, 6-tetrahydropyridine (MPTP), and alpha-synuclein toxicity (Jakel
et al., 2007; Jazwa et al., 2011; Lastres-Becker et al., 2012), while
activation of the Nrf2 pathway by triterpenoids attenuates MPTP
neurotoxicity (Kaidery et al., 2013). This has given rise to the notion
that Nrf2 responses might provide neuroprotection to patients with
PD (reviewed in Tufekci et al., 2011). The occurrence of strong nu-
clear localization of Nrf2 in the surviving substantia nigra neuronsin PD suggests a failing attempt to provide such protection and
counter oxidative stress (Ramsey et al., 2007).
Combination of lipoic acidwith other nutrients, such as acetyl-L-
carnitine and coenzyme Q has been proposed as providing addi-
tional beneﬁts (Liu, 2008).
3. Acetyl-L-carnitine
3.1. Role in energy metabolism
It is often assumed that glucose is the main source of energy in
the brain. However, the contribution from the oxidation of long
chain fatty acids should not be ignored especially in conditions of
relative starvation and during the night (Aureli et al., 1990). Fatty
acid oxidation yields large amounts of ATP. For example, the
complete oxidation of 1 molecule of palmitoyl-CoA yields 108
moles ATP, whereas 1 molecule of glucose yields 30 (a ratio of 7:5
ATP per carbon atom, respectively). The acetyl-CoA derived from
fatty acids can penetrate the outer membrane of mitochondria, but
is unable to cross the inner membrane. To gain access to the matrix
it must ﬁrst be converted to a carnitine derivative. This is achieved
by carnitine acting as an acyl-shuttle between carnitine acyl-
transferase I in the outer membrane, and carnitine acyltransferase
II plus a carrier protein on the inner membrane, yielding free
carnitine for recycling, while the acyl-CoA generated in the matrix
enters beta oxidation. The end product of this process, which
yields NADH and FADH2, is acetyl-CoA, which then enters the TCA
cycle for further metabolism (Zubay, 1998). This mechanism,
together with the age related loss of serum and mitochondrial
carnitine, provides a rationale for countering some of the effects
of aging on mitochondrial respiration with acetyl-L-carnitine
(ALC) (reviewed by Shigenaga et al., 1994).
ALC treatment appears to shift cerebral energy metabolism
away from glucose utilization toward glycogen synthesis (Aureli
et al., 1998) and to favor processing of citric acid cycle in-
termediates via increase in the activity of the rate limiting KGDH in
cerebral synaptic mitochondria (Gorini et al., 1998). In view of the
earlier discussion, this effect may be of beneﬁt in PD.
3.2. Effects on aging
Feeding old rats with ALC is able to counter age related decline in
tissue carnitine levels and improve fatty acid utilisation, but because
this increases electron ﬂow through the ETC, it may also produce an
increase in oxidative stress (Hagen et al., 1998). This problem is cir-
cumvented by coupling ALC with the antioxidant lipoic acid (LA).
In vivo, the combination of ALC þ LA results in partial reversal of age
related decline in the mitochondrial membrane potential, and oxy-
gen consumption, thus facilitating oxidative phosphorylation.
Further beneﬁts are restoration of the age related decrease in car-
diolipin (a phospholipid cofactor for protein complexes in the ETC),
restoration of age related changes in ascorbate and GSH, enhance-
ment of glucose uptake, reduced formation of lipid peroxidation
products malondialdehyde (MDA) and HNE, and reduction of the age
related accumulation of iron and copper (Hagen et al., 2002). These
ﬁndings obtained in hepatocytes, have been extended to brain
mitochondria and cortical tissue with similar results (Long et al.,
2009a; Suh et al., 2005), including normalization of GSH, superox-
ide dismutase, and protein carbonyl formation. However, the
reduction in complex I in old rats, is only partially restored. Futher-
more, the afﬁnities of complex I for cofactor coenzyme Q and sub-
strate NADH, which are lowered in old rats (an increase in Km), are
unchanged by ALC þ LA.
These biochemical ﬁndings have been complemented by elec-
tron microscopic studies of the brains of aged rats treated with
O.T. Phillipson / Neurobiology of Aging 35 (2014) 847e857850ALC þ LA (Aliev et al., 2009). While old control rats show half the
percentage of intact mitochondria compared with young controls,
treatment of old rats with ALCþ LA restores the numbers to young
control levels. Furthermore, the number of completely destroyed
mitochondria in old rats is halved by treatment.
Thus, the effect of ALC þ LA treatment in vivo appears to
signiﬁcantly hinder or reverse several factors underlying the vicious
cycle of age-related mitochondrial decay and hence cellular
dysfunction.
3.3. Effects in models of PD
ALC alone appears to be effective in primate models, providing
some, albeit weak protection against MPTP induced parkinsonism
(Bodis-Wollner et al., 1991). Studies of in vitro cell lines exposed to a
variety of mitochondrial inhibitors and uncoupling agents show that
both L-carnitine and ALC attenuate cell damage (Virmani et al.,1995).
Using an in vitro model of PD in which neuroblastoma cells are
exposed to the complex I inhibitor rotenone, pretreatment with a
combination of ALC þ LA protects against the inhibitor induced
loss of complex I, and reduction of mitochondrial membrane po-
tential, ATP, and GSH; and also reduces the level of protein and
DNA oxidation, accumulation of alpha-synuclein, ubiquitin, and
reactive oxygen species. In the absence of rotenone ALC þ LA in-
creases the number of viable mitochondria and mitochondrial
DNA expression, apparently via induction of the signaling mole-
cule PGC-1alpha; a regulator of the transcription factor for mito-
chondrial biogenesis and respiration. The combination exhibits
strong synergy as the agents together show 100e1000-fold
greater potency in several tests (including the PGC-1alpha assay)
when compared with individual use (Zhang et al., 2010).
A variety of experimental techniques show that PGC-1alpha
provides potent protection in vivo and in vitro against reactive
oxygen species, alpha-synuclein, rotenone, and MPTP induced
neurodegeneration (Mudo et al., 2012; St-Pierre et al., 2006;
Wareski et al., 2009; Zheng et al., 2010).
Signiﬁcantly, genome-wide meta-analysis of gene sets, indicates
that those sets involved in mitochondrial biogenesis and energy
metabolism, many of which respond to PGC-1alpha, appear to be
underactive in patients with PD compared with age matched con-
trols (Zheng et al., 2010).
3.4. Other gene functions
Additional inﬂuences on gene transcription relevant to neu-
roprotection by ALC have been reported. Treatment of cultured
astrocytes with ALC induces heme oxygenase-1 (HO-1), heat shock
protein 60, and the redox sensor Nrf2, as well as anti-
inﬂammatory signals (Calabrese et al., 2005). In vivo treatment
with ALC induces the gamma isoform of 14-3-3 protein and heat
shock protein 72 in rat brain (Traina et al., 2004). HO1 is a rate
limiting enzyme for the production of the potent antioxidant
bilirubin from heme and iron. Heat shock proteins are chaperones
which protect against damage by misfolded proteins, and gamma
14-3-3 is one of a family of 14-3-3 proteins acting as chaperones to
a very wide variety of proteins and nucleic acids. These responses
might thus contribute to a strategy to improve outcomes in PD via
protection from the risk of macromolecular oxidation and mis-
folding during aging.
3.5. Effects on neurotransmission
ALC has a variety of effects on neurotransmission (Jones
et al., 2010). Signiﬁcantly, ALC has beneﬁcial effects on the dopa-
minergic system of the aging brain. The 50% loss of D1 dopaminereceptor activity with age is reduced by prior ALC treatment, while
the electrically evoked stimulation of dopamine release from aged
striatal tissue is enhanced by in vivo pretreatment with ALC
(Sershen et al., 1991). Additional effects inﬂuence functional as-
pects of 5HT, noradrenergic, cholinergic, and gamma- amino-
butyric acid neurons (Imperato et al., 1989; Jones et al., 2010;
Smeland et al., 2012; Tempesta et al., 1985). The integrated effect
of these actions is as yet unclear, but the cholinergic responses
may have a role to play in reversing the age related decline in
cholinergic function and acetylcholine synthesis, and may inﬂu-
ence the pontine cholinergic cell loss in PD (Pahapill and Lozano,
2000). Pontine cholinergic neurons make direct excitatory syn-
aptic connection to the cell bodies of the nigro-striatal dopami-
nergic pathway (see Bolton et al., 1993).
3.6. Membrane functions
Many of the neuronal responses described previously may
result, not only from ALC acting via improved energy supply, and
gene activity, but also by acting more directly to provide acetyl
moieties to be used, for example in acetylcholine synthesis, or by
providing activated acyl groups for the acylation of membrane
phospholipids (Jones et al., 2010). These latter effects can mark-
edly affect membrane ﬂuidity and inﬂuence charge characteristics
of phospholipids, proteins, receptors, ion channels, uptake sites,
and membrane bound enzymes. Such effects may underlie the
beneﬁcial action of ALC on mitochondrial membranes, cardiolipin,
and the embedded complexes of the ETC (Shigenaga et al., 1994).
4. Coenzyme Q
Coenzyme Q (CoQ; ubiquinone) has a well established role as a
vital component of the ETC in the inner mitochondrial membrane,
where it undergoes redox cycling (the Q cycle) between complexes I
(NADH ubiquinone oxoreductase), II, and III. In the process it
indirectly supports the export of protons to maintain the mem-
brane potential across the inner membrane. This potential is
essential for ATP synthesis, which is dependent on reverse proton
chemiosmosis.
Coenzyme Q is also present outside mitochondria, and in
reduced form (ubiquinol) acts as an antioxidant in all tissues, pro-
tecting cell membrane lipids, phospholipids, proteins, and nucleic
acids from free radical damage (Ernster and Dallner, 1995).
4.1. CoQ and complex I in PD
CoQ10 deﬁciency has been reported in peripheral tissues from
patients with PD, including those with early untreated disease
(Mischley et al., 2012; Schults et al., 1997). Furthermore, there is a
highly signiﬁcant fall in the ratio of reduced to oxidized CoQ
(Sohmiya et al., 2004), suggesting a systemic state of oxidative
stress. In the central nervous system marked loss of CoQ has been
reported in the cerebral cortex, but not in substantia nigra, stria-
tum or cerebellum in PD (Hargreaves et al., 2008); interpreted as
reﬂecting cortical oxidative stress and consistent with change to
other oxidative stress markers found in cerebral cortex in PD
(Dalfo et al., 2005; Radunovic et al., 1997). These results should be
considered in the context of a normal age related decline of CoQ in
brain and other tissues (Spindler et al., 2009).
The transfer of electrons through the iron-sulfur complexes of
complex I involve the reduction of CoQ. The changes in CoQ found
in PD might thus result in part from the inhibition of complex I
activity in PD, which occurs not only in substantia nigra (Mann
et al., 1992; Schapira et al., 1990), but also in cerebral cortex and
many peripheral tissues (Parker et al., 2008). The origin of the
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generalized state of oxidative stress, which in turn occurs as part
of the normal process of aging (Long et al., 2009a). For example,
oxidized nitrogen species can irreversibly inhibit complex I in the
presence of low GSH (Clementi et al., 1998; Moncada and Bolanos,
2006). Other possibilities include oxidative damage to membrane
phospholipids and/or mitochondrial DNA, and xenobiotic chemi-
cal complex 1 inhibitors (Cleeter et al., 1992).
Taken along with evidence cited earlier for reduction in the
provision of NADH from the TCA cycle to fuel complex I and II
activity, these factors, together with underexpression of genes
associated with energy metabolism, contribute to impairments in
PD which threatens cellular integrity. Clearly the contribution of
normal aging to speciﬁc processes associated with PD should not be
ignored when considering supportive management. Furthermore,
thewidespread nature of oxidative stress and energy impairment in
PD is consistent with ﬁndings of neuropathologic changes in brain
areas outside dopaminergic pathways (Halliday, 2009; Jellinger,
1999) not only centrally, but also in peripheral tissues (e.g. Drolet
et al., 2009).
4.2. Experimental and clinical studies
In vitro cell culture studies have shown that CoQ protects against
the complex I inhibitors MPPþ and rotenone (Fontaine et al., 1998;
Gille et al., 2004; Moon et al., 2005) as well as the oxidative stress
induced by paraquat, H2O2 and transitional metals (Kooncumchoo
et al., 2006; McCarthy et al., 2004; Somajajulu et al., 2005).
Furthermore, CoQ can inhibit inﬂammatory responses, acting via
gene signaling (Kooncumchoo et al., 2006; Schmelzer et al., 2008).
In animal models, feeding CoQ is effective in raising brain
mitochondrial CoQ levels (Matthews et al., 1998), but the protection
offered by CoQ against the MPTP model of PD is only partial.
Against this background the clinical experience of CoQ mono-
therapy in PD has yielded conﬂicting results (Spindler et al., 2009)
and a recent phase III trial has shown that CoQ, although safe, is
ineffective in the long term (Clinical trials. gov, 2011).
4.3. CoQ and LA cooperation
Because the reduced form of CoQ (ubiquinol) needs to be
continually regenerated to sustain the Q cycle operating between
complexes I-III, and given the presence of a complex I deﬁciency in
PD, additional mechanisms to support recycling appear to be
needed. Such a mechanism appears possible by combining CoQ
with LA.
As noted previously, Nrf2 signals induced by LA results in the
expression of the antioxidant enzymes NQO1 and thioredoxin
reductase. Both of these enzymes appear able to reduce oxidized CoQ
to ubiquinol in the cytosol using extramitochondrial nicotinamide
adenine dinucleotide phosphate (NADPH) and NADH equally well
(Beyer et al., 1996; Xia et al., 2003). Reduced CoQ can then enter the
mitochondrial membrane to react with complex III, providing pro-
tons for export and electrons for the ETC. This also allows for an
electron bypass to compensate for complex I insufﬁciency.
Reducing equivalents may also be transferred from cytosolic
NADH to CoQ in the mitochondrial membrane via the glycerol-3-
phosphate shuttle (McKenna et al., 2006), but it is unknown
whether this route is enhanced as a result of Nrf2 signals.
NQO1 is especially useful to dopamine neurons, as it protects
the catechol moiety of dopamine from oxidation and so reduces
the consequent formation of further reactive oxygen species
(ROS). Furthermore, NQO1 induced by LA confers resistance to
peroxynitrite, H2O2 and 4HNE toxicity in a catecholamine cell line
in vitro (Jia et al., 2008). It may also control proteosomaldegradation of damaged or aggregated proteins (Dinkova-Kostova
and Talalay, 2010).
Taken together, the evidence suggests a potentially powerful
cooperative effect of combining CoQ and LA to provide neuro-
protection, especially to dopamine neurons in PD, using gene
expression evoked by Nrf2.
5. Melatonin
A substantial body of evidence exists (reviewed by Escames
et al., 2010) to suggest that some of the adverse risks associated
with the aging process and PD, including the reduction in mela-
tonin secretion with age, loss of GSH, complex I and antioxidant
control, may be managed by melatonin replacement.
5.1. Antioxidant defenses and mitochondrial functions
Numerous studies indicate that melatonin plays an important
role in antioxidant function and mitochondrial homeostasis.
Melatonin can gain access to all subcellular compartments with
ease, and while unequally distributed within the cell, it may accu-
mulate to levels of 100 nM in nuclei and mitochondria (Editorial,
2003). Many studies, however, used doses of melatonin well in
excess of what can be considered physiological.
Melatonin and some metabolites are excellent scavengers of
reactive oxygen and nitrogen species (Galano, 2011; Tan et al.,
2007). Following in vivo injection, melatonin increases the
messenger RNA (mRNA) for glutathione peroxidase, copper-zinc
superoxide, and manganese superoxide dismutase in rat brain
cortex. Interestingly, smaller doses result in larger effects (Kotler
et al., 1998). These enzymes form part of cellular defenses
against free radicals formed from H2O2, iron, NO, and superoxide.
In vitro experiments using neuronal cell lines have conﬁrmed that
physiological serum concentrations of melatonin produce large
increases in mRNA for both dismutases and glutathione peroxi-
dase (Mayo et al., 2002). Mitochondria do not contain catalase and
are thus largely dependent on GSH for antioxidant protection
against H2O2. Melatonin at 100 nM is able to restore GSH in iso-
lated GSH-depleted brain mitochondria, and increases glutathione
peroxidase and reductase activities (Martin et al., 2000). The
reductase acts to regenerate GSH from the oxidized disulphide
using NADPH as cofactor. Because GSH synthesis occurs mainly in
glial cells, the neuroprotection afforded by GSH is effected by glia-
neuronal cross talk. Melatonin at 100 nM protects the viability of
astrocytes against 200 mM H2O2 and produces a large increase in
mRNA for glutathione peroxidase induced by H2O2 (Martin et al.,
2002a).
In addition to improving antioxidant defenses, melatonin in-
creases the activity of enzyme complexes of the ETC, and the
production of ATP. In sub-mitochondrial particles, melatonin at
physiological concentrations (10e100 nM) increases the activity of
complex I and IV and the amount of ATP (Martin et al., 2002b). In
isolated liver mitochondria, melatonin at physiological concen-
trations protects against oxidative damage by reducing oxygen
consumption and the membrane potential, thus reducing super-
oxide and H2O2 production, while simultaneously maintaining the
efﬁciency of oxidative phosphorylation and ATP synthesis by
increasing mainly complex I and IV activity (Lopez et al., 2009). In
senescence accelerated mice there are signiﬁcant age associated
decreases in complex I and IV and glutathione peroxidase activ-
ities which are counteracted by daily melatonin in the drinking
ﬂuid (Okatani et al., 2002). The response of complex IV to mela-
tonin is greater than that of complex I, a result in agreement with
the in vitro ﬁndings (Lopez et al., 2009; Martin et al., 2000).
Melatonin has also been proposed as a signiﬁcant factor in the
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cardiolipin (Paradies et al., 2010).
Additional beneﬁts of melatonin for the functioning of the ETC
arise from the ability to preserve the nicotinamide nucleotides
NADPH and NADH. Preservation of NADPH promotes the activity of
glutathione reductase, thus maintaining GSH. Under conditions of
oxidative stress the interaction of superoxide with NADH generates
an NAD radical, setting up a vicious cycle of reactions leading to
reduced NADH levels. Melatonin can recycle the NAD radical to
NADH (Tan et al., 2005) thus preserving NADH as substrate for
complex I, facilitating ATP production.5.2. Role of nitric oxide
While the hydroxyl radical is often considered to be the main
toxic species produced in oxidative stress, via Fenton chemistry,
the high reactivity limits the extent of diffusion. Furthermore,
rate constants for synthesis are low, and endogenous defenses
should normally quench radical formation effectively. By contrast,
the formation of the powerful oxidant peroxynitrite (ONOO-)
from NO and superoxide proceeds a million times faster than the
Fenton reaction, and ONOO- diffusion exceeds that of the hy-
droxyl radical by a factor of 10,000. ONOO- efﬁciently oxidizes
-SH groups, lipids, proteins, and DNA. It can also produce stable
nitration of protein tyrosine residues, which may signiﬁcantly
disrupt phosphorylation reactions needed for signal transduction
(Beckman, 1994).
It has been noted previously (see section 2.3) that NO can
persistently inhibit complex I in the presence of low GSH.
Furthermore, in cultured dopaminergic neuronal cell lines, NO,
and ONOO- induce irreversible damage to complex I, tyrosine
nitration of complex I subunits, impaired mitochondrial respira-
tion, reduction in ATP synthesis and apoptotic cell death (Antunes
et al., 2002; Yamamoto et al., 2002). Because NO can give rise to a
wide variety of reactive nitrogen species (RNS), additional sources
of complex I inhibition are possible, and may include S-nitration,
release of iron, damage and disassembly of Fe-S clusters, modiﬁ-
cation of NADH, ubiquinone or ﬂavins, and oxidation of phos-
pholipids (Brown and Borutaite, 2004).
Against this background, it is highly signiﬁcant that the enzyme
responsible for generating NO, nitric oxide synthase (NOS), is
inhibited by melatonin at physiological concentrations (1 nM) in
striatum (Leon et al., 1998) cerebellum and hypothalamus (see
Reiter et al., 1998). Kinetic analysis of the puriﬁed neuronal
enzyme shows the inhibition to be non competitive, calcium/
calmodulin-dependent and that some kynurenine metabolites
may show even greater activity (Leon et al., 2000, 2006). In vivo
inhibition of NOS by 7-nitroindazole or melatonin (at high dose) or
a melatonin metabolite prevents complex I inhibition, tyrosine
nitration, and dopamine depletion produced in MPTP treated mice
(Schulz et al., 1995; Tapias et al., 2009).
The ability of melatonin to control the production of both ROS
and RNS by increasing dismutase and other antioxidant enzymes,
as well as via NOS inhibition, means that melatonin acts as a
powerful indirect antioxidant even at physiological concentra-
tions. Control of NOSmay be especially signiﬁcant because the rate
constant for ONOO- formation from NO and superoxide is three
times faster than that for removal of superoxide by dismutase
(Beckman, 1994).
It is well documented that aging is associated with marked
reductions in the nocturnal secretion of melatonin (Escames
et al., 2010). According to the evidence cited, this factor may
account for some of the oxidative and nitrosative damage risk
occurring in the aging process and in PD, speciﬁcally by failure ofadequate protection of mitochondria, including complex I and
GSH.
5.3. Melatonin and glial derived neurotrophic factor
In addition to the neuroprotective actions of melatonin
described previously, a neurorestorative role appears possible via
the ability to inﬂuence glial derived neurotrophic factor (GDNF).
Following the original puriﬁcation and cloning of this factor (Lin
et al., 1993), it has become apparent that GDNF has the potential
to reverse the continuing degeneration of dopamine neurons in PD.
However, technical problems have so far hampered progress in both
the experimental and clinical arena (Allen et al., 2013; Kirik et al.,
2004). Alternatively, it may become possible to stimulate regener-
ation given an understanding of the signaling pathways controlling
GDNF expression (Saavedra et al., 2008). In this respect, melatonin
or melatonin receptor agonists may prove useful.
Physiological doses of melatonin provide neuroprotection
against unilateral 6-hydroxydopamine induced rotation and loss
of tyrosine hydroxylase activity in an animal model of hemi-
parkinsonism (Sharma et al., 2006) associated with complex
changes in GDNF. In vitro rat C6 glioma cell lines, which express
both G protein coupled melatonin MT1 and MT2 receptor subtypes,
melatonin (0.1e100 nM) produces a dose dependent increase in
GDNF mRNA expression suggesting that MT1 receptor mediated
GDNF secretion might be beneﬁcial in PD (Armstrong and Niles,
2002). The neural stem cell line C17.2 similarly responds to mela-
tonin with enhanced GDNF mRNA expression (Niles et al. 2004).
Both MT1 and MT2 receptors are negatively coupled to the
adenyl cyclase cyclic adenosine monophosphate pathway. Activa-
tion by melatonin leads to suppression of cyclic adenosine mono-
phosphate and decrease in protein kinase A (PKA) and protein
phosphorylation, with resulting change in transcription factors and
gene expression via the Raf, MAPK/ERK pathway and hence activity
of speciﬁcity protein 1 and activating protein 2 (Masana and
Dubocovich, 2001). Both speciﬁcity protein 1 and activating pro-
tein 2 binding sites are present in the GDNF promoter, providing
nuclear receptors for information regulating GDNF transcription
(Baecker et al., 1999; Suter-Crazzolara and Unsicker, 1996; Verity
et al., 1998; Witt-Enderby et al., 2000; Woodbury et al., 1998).
Protein kinase A regulates the phosphorylation of cyclic adenosine
monophosphate response element binding protein, a factor which
also controls GDNF and brain-derived neurotrophic factor (BDNF)
expression via a binding site in the promoter region (Baecker et al.,
1999; Woodbury et al., 1998).
Melatonin regulates GDNF also via a second G(q/11) protein
pathway which mobilizes Caþþ. Activation of membrane bound
phospholipase C by Caþþ releases further Caþþ from intracellular
stores via inositol triphosphate to activate GDNF transcription.
Phospholipase C also increases diacyl glycerol which stimulates
phosphokinase C (PKC) (Armstrong and Niles, 2002; Brydon et al.,
1999; Verity et al., 1998). Melatonin can also stimulate puriﬁed PKC
directly (Anton-Tay et al., 1998; Hunt et al., 2001). In cultures of
human derived astrocytes, PKC inhibitors dramatically reduce
GDNF mRNA expression (Moretto et al., 1996), and stimulation of
PKC raises GDNF production in C6 cells (Verity et al., 1998).
Tyrosine hydroxylase (the rate limiting enzyme for dopamine
synthesis) is induced by melatonin, acting probably via the MAPK/
ERK pathway (McMillan et al., 2007), i.e., in commonwith one route
used by melatonin for GDNF expression.
6. Discussion
Efforts to manage dysfunctional mitochondria in PD have thus
far proved ineffective (Swerdlow, 2009), since no single agent has
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and gene activities. Here, the properties of four agents have
been analyzed to show that, together, they appear to provide
the necessary protection against known risks of the aging process
with respect to PD. The combination of LA, ALC, CoQ, and
nocturnal melatonin can improve defenses against oxidative and
nitrosative stress, enhance energy metabolism via carbohydrate
and fatty acid utilization, assist mitochondrial electron transport
and ATP synthesis, and promote defenses against protein mis-
folding, inﬂammatory stimuli, iron, and other endogenous or
xenobiotic toxins. These properties allow disease risk factors,
outlined in the introduction, which are common to both aging and
PD to be addressed. Case history evidence that these aging risks
associated with PD can be managed effectively by this combina-
tion to inhibit progression (Phillipson, 2013) is consistent with
the observed association of aging as the major risk factor for the
sporadic form of PD.
Many of the properties of this combination are associated with,
and may result from, changes to gene regulation, for example via
increased expression of the antioxidant response element (ARE;
Keap/Nrf2/ARE pathway) as outlined previously, and the induc-
tion of PGC-1alpha; the latter resulting in stimulation of mito-
chondrial biogenesis and improved mitochondrial morphology. In
addition, PGC-1alpha and Nrf2 interact mutually and induce nu-
clear respiratory factor 1, which activates mitochondrial tran-
scription factor A (Tfam), a protein regulator of mitochondrial
DNA transcription, translation, and repair (see Tufekci et al., 2011)
thus providing protection against age-related mitochondrial DNA
damage. Underexpression of PGC-1alpha responsive genes has
been found in PD compared with age-matched controls (Zheng
et al., 2010). These include gene “sets” which are associated
with pyruvate metabolism, the TCA cycle, electron transport,
oxidative phosphorylation and other mitochondrial, and glucose
sensing genes. Furthermore, these gene sets appear underex-
pressed, not only in dopamine, but also in non-dopamine and
extraneural tissues in PD, as well as in preclinical incidental Lewy
body disease. Taken together, this evidence suggests that widely
distributed abnormalities in energy metabolism are associated
with the origins and development of PD, and that this plays some
part in explaining the effectiveness of this combination of sup-
plements in counteracting progression, speciﬁcally via the syn-
ergistic ability of LA and ALC to induce PGC-1alpha (Zhang et al.,
2010). However, it should be emphasized that this action via
gene expression for both the ARE pathway and PGC-1alpha, ap-
pears, by itself, insufﬁcient to counter disease risks in PD
(Phillipson, 2013), and that CoQ is also required, presumably to
support the Q cycle for electron transport between complexes
IeIII, and help circumvent complex I inhibition in cooperation
with Nrf2 signaling as described previously. Additional nocturnal
support of antioxidant defense is provided by melatonin.
The sensitivity of catecholamine neurons to conditions of oxida-
tive stress, and the protective properties of glutathione to the cate-
chol moiety of dopamine are well known (Cohen, 1994). Glutathione
also protects against the oxidative properties of H2O2 normally
produced during the metabolism of dopamine via monoamine oxi-
dase (MAO). Conditions of low glutathione in aging and in PD thus
increase risks of oxidative and nitrosative damage to dopamine
neurons, which can be addressed by Nrf2 signaling andmelatonin as
described previously. Similar protection is provided against the age-
related increase in glial MAO-B, which poses risks to KGDH and
complex I activity via increased H2O2 production (Kumar et al.,
2003).
The metabolism of dopamine to dihydroxyphenylacetaldehyde
(DOPAL) via MAO-A, presents additional risks to dopamine neu-
rons during aging. Normally DOPAL is rapidly converted to inertmetabolites, mainly via ALDH, but in raised concentration DOPAL
is toxic to dopamine neurons producing stable protein adducts
and cross-linking (reviewed in Marchitti et al., 2007). Aging pro-
duces profound reduction in the essential ALDH cofactor NADþ
(Braidy et al., 2011), and increased production of lipid peroxida-
tion products MDA and HNE. These in turn inhibit ALDH activity
and are capable of increasing DOPAL levels by 5e10-fold. In
addition, DOPAL can inhibit ALDH via protein adduction, even
though it is the normal substrate. In spite of these risks, however,
complete inhibition of DOPAL metabolism producing a 5e6-fold
increase in DOPAL does not produce toxicity in cultured PC12
cells with a healthy metabolism. Only when there is accompa-
nying metabolic and mitochondrial stress does DOPAL toxicity
become apparent (Kristal et al., 2001; Lamensdorf et al., 2000).
These observations directly demonstrate the crucial importance of
mitochondrial functions in the protection of dopamine neurons
and explain at least in part the special liability of these neurons to
undergo degenerative change in aging and especially in PD. A
similar process applies to noradrenergic neurons which also
degenerate in PD.
In the context of the present article, the support ofmitochondrial
function as described seems well suited to reduce these risks of
catecholamine oxidation and DOPAL toxicity, since Nrf2 and PGC-
1alpha signaling increase both glutathione and ALDH, reduces
lipid peroxidation and hence MDA and HNE, and aids a variety of
mitochondrial functions including support of gene expression for
energy metabolism. Further neuroprotection may be provided via
control of toxic alpha-synuclein oligomers and aggregates, which
may arise as a result of the reaction between DOPAL and alpha-
synuclein (Burke et al., 2008).
The protein alpha-synuclein appears to play an important role
in PD pathogenesis, as it forms the major component of Lewy
bodies (LB) and neurites, found in both dopamine and non-
dopamine neurons. Normal aging is associated with marked in-
crease in alpha-synuclein in the substantia nigra in humans, but
this is in a diffuse and soluble form, and is not localized in LB form
as it is in PD (Chu and Kordower, 2007). However, reactive oxygen
species can result in alpha-synuclein aggregation, and the LB
contains oxidized and nitrated forms of alpha-synuclein (Giasson
et al., 2000). Such misfolding and accumulation risks the loss of
one physiological function of alpha-synuclein, namely regulation
of mitochondrial Caþþ uptake from the endoplasmic reticulum
(Cali et al., 2012) with consequent disruption of Caþþ homeo-
stasis. Furthermore, misfolded alpha-synuclein impairs complex I,
ATP synthesis, and the mitochondrial membrane potential, pro-
ducing further oxidative stress, microglial activation and neuro-
inﬂammation (Chinta et al., 2010; Devi et al., 2008; Dunning et al.,
2013). The signiﬁcance of these events for pathogenesis of age
related PD is illustrated by alpha-synuclein gene mutations, which
are associated with the rare autosomal dominant form of PD (see
Dunning et al., 2013).
Protection against these events may be achieved by the
combination of LA þ ALC, which reduces the accumulation of
alpha-synuclein (Zhang et al., 2010), and activates antioxidant
Nrf2 signals. These may reduce protein misfolding produced by
oxidative stress, and reduce the aggregates generated by protein
cross-linking in the presence of DOPAL by enhancing DOPAL
metabolism via ALDH. Additional protection may be afforded by
melatonin, which prevents oligomerization and all stages of
ﬁbril formation in alpha-synuclein resulting in reduced
neuronal cytotoxicity (Ono et al., 2012). These properties may
thus also play a role in the ability of this combination to
counter disease progression (Phillipson, 2013), since misfolded
alpha-synuclein apears to be involved in the spreading of PD
pathology (Braak et al., 2003; Dunning et al., 2013).
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have the potential to support a neurorestorative role. The mela-
tonin MT1 receptor is present in human brain in all major dopa-
minergic regions (Uz et al., 2005). However, it remains to be
determined whether melatonin retains the capacity to support
GDNF expression via MT1 activity, given that melatonin receptors
are reduced in PD (Adi et al., 2010). Furthermore, the complexity of
intracellular signals following melatonin receptor stimulation (see
section 5.3) suggests that the outcome with respect to GDNF is
likely to depend on other factors. For example, activity via Nrf2
stimulation of HO-1 expression may be signiﬁcant (Surh et al.
2009), as HO-1 has the potential to increase both GDNF and
BDNF and their mRNA scripts in substantia nigra (Hung et al.,
2008, 2010). Furthermore, since PKC is proposed as an upstream
activator of both Nrf2 (Giudice et al. 2010; Tufecki et al., 2011)
and GDNF, activation of PKC bymelatonin as described (see section
5.3) may amplify this Nrf2/HO-1/GDNF signal pathway. It remains
to be determined whether this allows for synergy to operate be-
tween LA þ ALC driven Nrf responses and melatonin in respect of
GDNF. Additional potential synergy between melatonin and
CoQ10 via the phosphatidylinositide 3-kinase (PI3K) pathway
(Choi et al., 2012; Kong et al., 2008) also requires investigation as
to GDNF production. Furthermore, since HO-1 mediated GDNF
expression also appears to utilize PI3K (Hung et al., 2010), LA, ALC,
CoQ10, and melatonin may all have a role to play in the regulation
of GDNF.
7. Safety
The nutrients discussed in this article have all been used for de-
cades in a variety of clinical situations. Thus so far they do not appear
to have raised serious safety issues, and they seem to be well toler-
ated, and appear to lack signiﬁcant side effects or signs of toxicity as
revealed in laboratory tests (Clinical Trials.gov. 2011; Cremer et al.,
2006; de Grandis et al., 2002; Lemoine et al., 2011; Seabra et al.,
2000; Shay et al., 2009; Spindler et al., 2009). The doses required to
control the aging risk factor in the PD case history described
(Phillipson, 2013), are less than those used in these long term studies.
In particular, for melatonin, a method of physiological nocturnal
administration is employed (Lemoine et al., 2011).
8. Conclusions
This article outlines a variety of factors which appear to un-
derlie the association of aging with the risks of developing the
sporadic form of PD, and analyses the actions and potential syn-
ergies of four agents which effectively manage these risks as
judged by experimental and case history evidence. Although there
are also evident distinctions to be drawn between underlying
events in normal aging and PD (Darbin, 2012; Hindle, 2010; Kish
et al., 1988; Kish et al., 1992; Zheng et al., 2010), the result that
the effective management of known speciﬁc risks to energy
metabolism, mitochondrial functions, and gene expression asso-
ciated with aging, can deliver an improved outcome in PD, em-
phasizes the links between these apparently different conditions.
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